Roche(RHHBY) - 2024 Q2 - Earnings Call Presentation

Roche HY 2024 results Thomas Schinecker Chief Executive Officer HY 2024: Strong business performance in both divisions • Diagnostics regulatory: cobas c703 and ISE neo (EU), cobas Liat Respiratory Panel FDA EUA, cobas pro serology solution (FDA), Accu-Chek SmartGuide CGM (EU), VENTANA Kappa Lambda Dual ISH mRNA Probe Cocktail (EU), HPV self-collection solution (FDA) • Pivotal readouts: Ph III (REGENCY) Gazyva in LN and Ph III (SKYSCRAPER-01) tiragolumab in 1L NSCLC Roche Any statements regarding earnings pe ...